[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349578-105":59,"doc-detail-349578-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mechanisms-of-paclitaxel-resistance-recent-advances-and-future-perspectives","Mechanisms of Paclitaxel Resistance - Recent Advances and Future Perspectives","","Paclitaxel (PTX) is a core first-line chemotherapeutic agent used across a broad range of cancers, yet intrinsic and acquired resistance often drives chemotherapy failure, tumor recurrence, metastasis, and poor prognosis. PTX resistance arises from complex, multi-factor biology and cross-regulated signaling pathways, including microtubule-related alterations, mitotic system changes and chromosomal instability, epigenetic regulation, drug efflux and apoptosis/proliferation signaling dysregulation, protective autophagy, metabolic reprogramming, cell plasticity, tumor microenvironment remodeling, and immune regulation. This review organizes molecular mechanisms, summarizes strategies to reverse chemoresistance with clinical translation, and outlines challenges and future directions to guide optimization of PTX-based regimens.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mechanisms-of-paclitaxel-resistance-recent-advances-and-future-perspectives/349578/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mechanisms-of-paclitaxel-resistance-recent-advances-and-future-perspectives/349578.png","ImageObject",300,407,{"name":92,"@type":93},"LangkahRina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is paclitaxel resistance a major clinical problem?","Question",{"text":112,"@type":113},"Paclitaxel resistance undermines chemotherapy efficacy, contributing to treatment failure. It also promotes tumor recurrence and metastasis, leading to poor patient prognosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What kinds of mechanisms drive paclitaxel resistance?",{"text":117,"@type":113},"Resistance is driven by multiple interacting factors, including microtubule/protein aberrations, mitotic changes and chromosomal instability, epigenetic modifications, enhanced drug efflux, dysregulated proliferation and apoptosis signaling, protective autophagy, metabolic reprogramming, cell plasticity (EMT and stemness), tumor microenvironment remodeling, and immune regulation.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review help clinicians and researchers?",{"text":121,"@type":113},"It systematically summarizes core molecular mechanisms, consolidates cutting-edge strategies aimed at reversing chemoresistance, and discusses clinical translation, remaining challenges, and future directions to optimize PTX-based regimens.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349578,1790580489,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":24,"preview_urls":146},962090893776,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Review  \nMechanisms of Paclitaxel Resistance: Recent Advances and Future Perspectives  \nJialong Xie 1,2,3, Xingxuan Ren 4,5,6, Zhibin Wang 2,3, * and Weidong Xie 4,5,6, *  \nAcademic Editor: Abby Parrill  \nReceived: 1 July 2026  \nRevised: 6 August 2026  \nAccepted: 8 August 2026  \nPublished: 11 August 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518055, China; [suat25060190@stu.suat-sz.edu.cn](suat25060190@stu.suat-sz.edu.cn)  \n2 Department of Biopharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology, Shenzhen 518107, China  \n3 Center for Cancer Immunotherapy, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China  \n4 Shenzhen Key Laboratory of Health Science and Technology, Institute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China; [rxx25@mails.tsinghua.edu.cn](rxx25@mails.tsinghua.edu.cn)  \n5 Open FIESTA (Faculty for Innovation, Education, Science, Technology and Art) Center, Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China  \n6 State Key Laboratory of Chemical Oncogenomics, Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China  \n* [Correspondence: wangzhibin@suat-sz.edu.cn](Correspondence: wangzhibin@suat-sz.edu.cn) (Z.W.); [xiewd@sz.tsinghua.edu.cn](xiewd@sz.tsinghua.edu.cn) (W.X.)  \nAbstract  \nPaclitaxel (PTX) is a core first-line chemotherapeutic agent used to treat a broad spectrum of cancers, which remain leading causes of death worldwide. However, the emergence of intrinsic and acquired resistance critically contributes to chemotherapy failure, thereby promoting tumor recurrence and metastasis and resulting in a poor prognosis. PTX resistance is a complex biological process driven by multiple factors and cross-regulated signaling pathways. It encompasses a wide variety of mechanisms, including aberrations in microtubules and related proteins; changes in mitotic systems and chromosomal instability (CIN); epigenetic modifications including ncRNA regulation, DNA methylation, and histone modification; enhanced drug efflux and dysregulation of proliferation and apoptotic signaling pathways; enhanced protective autophagy; metabolic reprogramming; cell plasticity (increased EMT and cancer cell stemness); TME remodeling; and immune regulation. This review systematically examines the core molecular mechanisms of PTX resistance, summarizes cutting-edge strategies to reverse chemoresistance and their clinical translation, and discusses current challenges and future directions, thereby providing a theoretical framework for optimizing PTX-based regimens and overcoming clinical resistance.  \nKeywords: cancer; drug resistance; paclitaxel  \n1. Introduction  \n1.1. Current Status of Cancer Epidemiology and Challenges in Clinical Diagnosis and Treatment  \nCancer remains a leading cause of death worldwide and a major global health challenge, with persistently high incidence rates [1] . Lung cancer, breast cancer, and colorectal cancer are among the most common malignancies in the world [2–4] . Cancer treatment primarily includes surgery, radiation therapy, and drug therapy. Surgery is generally restricted to early-stage cancer, and radiation therapy often causes significant side effects; consequently, systemic drug therapy constitutes the mainstay of treatment for the majority  \nof patients [5] . In recent years, various forms of systemic therapy have advanced rapidly, including classical chemotherapy, targeted therapy, immunotherapy, and epigenetic drugs, including antibody–drug conjugates (ADCs) and proteolysis-targeting chim","cbCaikirGaIhMeqm","https://ap.wps.com/l/cbCaikirGaIhMeqm","pdf",1562223,41,"English","# Introduction\n## Current Status of Cancer Epidemiology and Challenges in Clinical Diagnosis and Treatment\n## Clinical Challenges in the Use of PTX and Drug Resistance\n# Abstract\n# Keywords","[{\"question\":\"Why is paclitaxel resistance a major clinical problem?\",\"answer\":\"Paclitaxel resistance undermines chemotherapy efficacy, contributing to treatment failure. It also promotes tumor recurrence and metastasis, leading to poor patient prognosis.\"},{\"question\":\"What kinds of mechanisms drive paclitaxel resistance?\",\"answer\":\"Resistance is driven by multiple interacting factors, including microtubule/protein aberrations, mitotic changes and chromosomal instability, epigenetic modifications, enhanced drug efflux, dysregulated proliferation and apoptosis signaling, protective autophagy, metabolic reprogramming, cell plasticity (EMT and stemness), tumor microenvironment remodeling, and immune regulation.\"},{\"question\":\"How does the review help clinicians and researchers?\",\"answer\":\"It systematically summarizes core molecular mechanisms, consolidates cutting-edge strategies aimed at reversing chemoresistance, and discusses clinical translation, remaining challenges, and future directions to optimize PTX-based regimens.\"}]","Mechanisms of Paclitaxel Resistance - Recent Advances and Future Perspectives | PDF",1790084384,103,[147,151,155,159,163],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da8cf7135bd39b1e2652aa9b2f1ff2e5.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61e6ca7b9960ff075775787355f94fc3.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5029a17fe98e36c61a8f6c77e71fb016.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c6b682978edf2efab79b880d2d18309.webp",980,1385,{"page_no":24,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a14eea9ed3e9def33e1b9c46f76996cd.webp",979,1384]